These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38852646)

  • 1. INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib.
    Qu N; Wang G; Su Y; Chen B; Zhou D; Wu Y; Yuan L; Yin M; Liu M; Peng Y; Zhou W
    Biochem Pharmacol; 2024 Jun; 226():116347. PubMed ID: 38852646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma.
    Tang W; Yang L; Yang T; Liu M; Zhou Y; Lin J; Wang K; Ding C
    Onco Targets Ther; 2019; 12():3491-3507. PubMed ID: 31123408
    [No Abstract]   [Full Text] [Related]  

  • 3. INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.
    Chen H; Li H; Chen Q
    Biochem Biophys Res Commun; 2016 Aug; 477(3):467-72. PubMed ID: 27318090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.
    Li D; Yang J; Ma H; Sun C; Feng R
    J Cell Biochem; 2018 Dec; 119(12):9899-9909. PubMed ID: 30132953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W
    Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
    Fedele CG; Ooms LM; Ho M; Vieusseux J; O'Toole SA; Millar EK; Lopez-Knowles E; Sriratana A; Gurung R; Baglietto L; Giles GG; Bailey CG; Rasko JE; Shields BJ; Price JT; Majerus PW; Sutherland RL; Tiganis T; McLean CA; Mitchell CA
    Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22231-6. PubMed ID: 21127264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.
    Rodgers SJ; Ooms LM; Oorschot VMJ; Schittenhelm RB; Nguyen EV; Hamila SA; Rynkiewicz N; Gurung R; Eramo MJ; Sriratana A; Fedele CG; Caramia F; Loi S; Kerr G; Abud HE; Ramm G; Papa A; Ellisdon AM; Daly RJ; McLean CA; Mitchell CA
    Nat Commun; 2021 May; 12(1):3140. PubMed ID: 34035258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INPP4B inhibits glioma cell proliferation and immune escape
    Sun X; Chen Y; Tao X; Zhang W; Wang X; Wang X; Ruan Z; Chen Z
    Front Oncol; 2022; 12():983537. PubMed ID: 36147923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The INPP4B paradox: Like PTEN, but different.
    Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
    Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
    Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INPP4B exerts a dual role in gastric cancer progression and prognosis.
    Wu Y; Wang X; Lu Y; Wang H; Wang M; You Y; Su X; Sun D; Sun Y; Li Y
    J Cancer; 2021; 12(23):7201-7213. PubMed ID: 34729121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells.
    Wu Y; Meng D; Xu X; Bao J; You Y; Sun Y; Li Y; Sun D
    BMC Cancer; 2021 Apr; 21(1):433. PubMed ID: 33879096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
    Reed DE; Shokat KM
    Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNER promotes epithelial-mesenchymal transition and prevents chemosensitivity through the Wnt/β-catenin pathway in breast cancer.
    Wang Z; Li Z; Wu Q; Li C; Li J; Zhang Y; Wang C; Sun S; Sun S
    Cell Death Dis; 2020 Aug; 11(8):642. PubMed ID: 32811806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
    Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
    Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma.
    Wang Y; Chen L; Li Q; Gao S; Liu S; Ma J; Xie Y; Wang J; Cao Z; Liu Z
    Front Oncol; 2021; 11():785297. PubMed ID: 35070988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
    Chen Y; Sun Z; Qi M; Wang X; Zhang W; Chen C; Liu J; Zhao W
    J Cell Mol Med; 2018 May; 22(5):2935-2943. PubMed ID: 29516642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells.
    Chen H; Li H; Chen Q
    Clin Exp Pharmacol Physiol; 2017 Jun; 44(6):700-708. PubMed ID: 28261855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.
    Nami B; Wang Z
    Cancers (Basel); 2017 Apr; 9(5):. PubMed ID: 28445439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.